OncoMatch/Clinical Trials/NCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction
Is NCT05909059 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fludarabine and Cyclophosphamide for non-hodgkin lymphoma,b cell.
Treatment: Fludarabine · Cyclophosphamide — This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Multiple Myeloma
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: CAR-T cell therapy — commercial
Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration
Lab requirements
Blood counts
Adequate bone marrow function to receive lymphodepleting chemotherapy
Kidney function
Renal function </= 60mL/min/1.73m2
Adequate bone marrow function to receive lymphodepleting chemotherapy; Renal function </= 60mL/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Caitlin Guzowski · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify